Markets
EBS

OXiGENE (OXGN) to Initiate Two Phase II/III Studies on CA4P

OXiGENE, Inc.OXGN announced its plans to conduct two phase II/III randomized studies on CA4P (combretastatin A4 phosphate, or fosbretabulin) for the treatment of ovarian cancer and glioblastoma multiforme (GBM).

The first phase II/III study will be carried out in patients with platinum-resistant ovarian cancer, with the goal of determining whether the addition of CA4P to chemotherapy plus Avastin (bevacizumab) improves patient outcomes. The study is expected to be initiated in the first half of 2016.

The second study will be initiated in patients with GBM who have failed first-line chemotherapy treatment, with the goal of determining whether CA4P improves upon the current treatment of Avastin as monotherapy. The company expects to initiate this study in the second half of 2016.

Based on the greater commercial potential of the currently planned study, the company said that it does not intend to evaluate CA4P plus Avastin without chemotherapy or submit a Special Protocol Assessment for the same.

According to information provided by the company, approximately 22,000 women are diagnosed with ovarian cancer each year in the U.S. Out of this figure 4,300 women are resistant to platinum-based therapies. Additionally, approximately 11,000 patients are diagnosed with GBM each year in the U.S., out of which 6,000 are considered recurrent.

Meanwhile, OXiGENE continues to evaluate CA4P in two ongoing studies. The candidate is being evaluated in combination with Votrient (pazopanib) in a phase Ib/II study for the treatment of advanced recurrent ovarian cancer. Initial data is expected to be presented at the European Society of Gynaecological Oncology conference in Oct 2015. In addition, CA4P is being studied as monotherapy in a phase II study for the treatment of patients with gastrointestinal and pancreatic neuroendocrine tumors. Interim data is expected by year-end.

We note that the company is also progressing on OXi4503 which is currently in a phase I study for the treatment of patients with acute myeloid leukemia.

OXiGENE carries a Zacks Rank #4 (Sell). Some better-ranked stocks in the health care sector are Emergent BioSolutions, Inc. EBS , Nexvet Biopharma Public Limited Co. NVET and Regeneron Pharmaceuticals, Inc. REGN , each sporting a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

OXIGENE INC (OXGN): Free Stock Analysis Report

REGENERON PHARM (REGN): Free Stock Analysis Report

EMERGENT BIOSOL (EBS): Free Stock Analysis Report

NEXVET BIOPHARM (NVET): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

EBS REGN

Other Topics

Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More